The risk that the domestic pharmaceutical market will shift from its previous growth phase to a period of stagnation or slower growth, resulting in significant changes in the market environment. This covers the growth prospects of the domestic pharmaceutical market as a whole and changes in its environment, rather than being limited to specific drug pricing policies, generic drug penetration, regulatory changes or competitive factors.